Clinical Trials Directory

Trials / Completed

CompletedNCT01975441

Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
182 (actual)
Sponsor
University Hospitals Cleveland Medical Center · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given to treat this infection. The three drugs used together are called albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC). The usual treatment in Papua New Guinea (PNG) for lymphatic filariasis are DEC and ALB. A combination of these 3 drugs has not been previously used to treat LF.

Detailed description

This study will determine whether a single dose of the triple drug regimen of DEC/Iver/Alb is non-inferior to annual treatments with DEC/Alb in inducing sustained clearance of Mf in LF infected subjects (\>50 Mf/ml) at 36 months post-treatment. This study also tests the hypothesis that single dose of triple drug is super in sustained clearance of microfilariae compared to single dose of DEC/ALB. There will be 3 treatment arms as follows: 1. The comparator (standard treatment) DEC 6 mg/kg + Alb 400 mg administered annually (at 0, 12, and 24 months). 2. DEC 6 mg/kg + Alb 400 mg given once 3. DEC 6 mg/kg + Alb 400 mg + Iver 200 µg/kg administered once only at the beginning of the RCT (0 month).

Conditions

Interventions

TypeNameDescription
DRUGDiethylcarbamazineDiethylcarbamazine 6mg/kg
DRUGAlbendazoleAlbendazole 400mg
DRUGIvermectinIvermectin 200 mcg/kg

Timeline

Start date
2014-05-01
Primary completion
2017-12-01
Completion
2018-06-01
First posted
2013-11-04
Last updated
2018-10-09

Locations

1 site across 1 country: Papua New Guinea

Source: ClinicalTrials.gov record NCT01975441. Inclusion in this directory is not an endorsement.